The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase–mediated suppression of histone deacetylase 2
Open accessAbstract
Background: Severe steroid‐insensitive asthma is a substantial clinical problem. Effective treatments are urgently required, however, their development is hampered by a lack of understanding of the mechanisms of disease pathogenesis. Steroid‐insensitive asthma is associated with respiratory tract infections and noneosinophilic endotypes, including neutrophilic forms of disease. However, steroid‐insensitive patients with eosinophil‐enriched inflammation have also been described. The mechanisms that underpin infection‐induced, severe steroid‐insensitive asthma can be elucidated by using mouse models of disease. Objective: We sought to develop representative mouse models of severe, steroid‐insensitive asthma and to use them to identify pathogenic mechanisms and investigate new treatment approaches. Methods: Novel mouse models of Chlamydia, Haemophilus influenzae, influenza, and respiratory syncytial virus respiratory tract infections and ovalbumin‐induced, severe, steroid‐insensitive allergic airway disease (SSIAAD) in BALB/c mice were developed and interrogated. Results: Infection induced increases in the levels of microRNA (miRNA)‐21 (miR‐21) expression in the lung during SSIAAD, whereas expression of the miR‐21 target phosphatase and tensin homolog was reduced. This was associated with an increase in levels of phosphorylated Akt, an indicator of phosphoinositide 3‐kinase (PI3K) activity, and decreased nuclear histone deacetylase (HDAC)2 levels. Treatment with an miR‐21–specific antagomir (Ant‐21) increased phosphatase and tensin homolog levels. Treatment with Ant‐21, or the pan‐PI3K inhibitor LY294002, reduced PI3K activity and restored HDAC2 levels. This led to suppression of airway hyperresponsiveness and restored steroid sensitivity to allergic airway disease. These observations were replicated with SSIAAD associated with 4 different pathogens. Conclusion: We identify a previously unrecognized role for an miR‐21/PI3K/HDAC2 axis in SSIAAD. Our data highlight miR‐21 as a novel therapeutic target for the treatment of this form of asthma. GRAPHICAL ABSTRACT Figure. No caption available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer
Meng, F., Henson, R., Wehbe–Janek, H., Ghoshal, K., Jacob, S. T., & Patel, T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.022 · Cited by 2,773
miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis
Liu, G., Friggeri, A., Yang, Y., Milosevic, J., Ding, Q., Thannickal, V. J., Kaminski, N., & Abraham, E. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100035 · Cited by 935 · cited 1×
“In addition to the miR-21–dependent responses that are described in the current study, miR-21 and/or PTEN/PI3K responses have also been implicated in other disease processes in the lung, including profibrotic responses in patients with idiopathic pulmonary fibrosis, enhanced accumulation of myofibroblasts, and allerge…”
Tay, H. L., Kaiko, G. E., Plank, M., Li, J., Maltby, S., Essilfie, A.-T., Jarnicki, A., Yang, M., Mattes, J., Hansbro, P. M., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004549 · Cited by 67
Self-citation
Cited by
Role for NLRP3 Inflammasome–mediated, IL-1β–Dependent Responses in Severe, Steroid-Resistant Asthma
Kim, R. Y., Pinkerton, J. W., Essilfie, A. T., Robertson, A. A. B., Baines, K. J., Brown, A. C., Mayall, J. R., Ali, M. K., Starkey, M. R., Hansbro, N. G., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1830oc · Cited by 435
Self-citationEpigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages
Runtsch, M. C., Angiari, S., Hooftman, A., Wadhwa, R., Zhang, Y., Zheng, Y., Spina, J. S., Ruzek, M. C., Argiriadi, M. A., McGettrick, A. F., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.002 · Cited by 323
Self-citationAgache, I., & Akdis, C. A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124611 · Cited by 313
Targeting cell signaling in allergic asthma
Athari, S. S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0079-0 · Cited by 312
Metadata
- Authors
- Kim, R. Y., Horvat, J. C., Pinkerton, J. W., Starkey, M. R., Essilfie, A. T., Mayall, J. R., Nair, P. M., Hansbro, N. G., Jones, B., Haw, T. J., Sunkara, K. P., Nguyen, T. H., Jarnicki, A. G., Keely, S., Mattes, J., Adcock, I. M., Foster, P. S., & Hansbro, P. M.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 139
- Issue
- 2
- Pages
- 519-532
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2412707497
- Cited by
- 210
- References
- 5
- FWCI
- 17.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.